RING finger E3 ubiquitin ligases: Structure and drug discovery

Current Pharmaceutical Design

Volumn 15, Issue 31, 2009, Pages 3716-3731

  Chasapis, Christos T ^a   Spyroulias, Georgios A ^a  

^a UNIVERSITY OF PATRAS   (Greece)

Author keywords

Anticancer drugs; E3 ubiquitin ligase; RING finger; Ubiquitin; Zinc coordination

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; AG 0146999; BENZODIAZEPINE; BRCA1 PROTEIN; CBL PROTEIN; CYCLIN DEPENDENT KINASE ACTIVATING KINASE; ENZYME INHIBITOR; MURIINE DOUBLE MINUTE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PROTEIN ARKADIA; PROTEIN BCA2; PROTEIN MAT1; PROTEIN MDM2; PROTEIN NRDP1; PROTEIN P53; PROTEIN POSH; PROTEIN RNF11; PROTEIN SKI; PROTEIN SNON; RING FINGER E3 UBIQUITIN LIGASE; TRAF 6; TUMOR MARKER; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE E3 INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; APOPTOSIS; BINDING SITE; CANCER CELL; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CELL CYCLE ARREST; CLINICAL TRIAL; DIMERIZATION; DNA REPAIR; DRUG POTENCY; DRUG RESEARCH; DRUG TARGETING; ENZYME ACTIVITY; ENZYME BINDING; ENZYME PURIFICATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; GROWTH INHIBITION; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HYDROPHOBICITY; IC 50; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; STRUCTURE ANALYSIS; X RAY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; NEOPLASMS; PROTEIN CONFORMATION; RING FINGER DOMAINS; UBIQUITIN-PROTEIN LIGASES;

EID: 70449564474     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209789271825     Document Type: Review

References (133)

1. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67: 425-479
2. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 1998; 17: 7151-7160 (Pubitemid 29002684)
3. Varshavsky A. The N-end rule and regulation of apoptosis. Nat Cell Biol 2003; 5: 373-376
4. Varshavsky A. The N-end rule pathway of protein degradation. Genes Cells 1997; 2: 13-28. (Pubitemid 127688555)
5. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75: 495-505. (Pubitemid 23335075)
6. Jakson PK, Eldridge AG, Freed E, Furstenthal L, Hsu JY, Kaiser BK, Reimann JDR. The lore of the RINGs: substrate recognition and catalysis by ubiquitin ligases. Trends Cell Biol 2000; 10: 429-439 (Pubitemid 30682364)
7. Mani A, Gelmann EP. The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 2005; 23: 4776-4789 (Pubitemid 46224082)
8. Borden KL, Freemont PS. The RING finger domain: a recent example of a sequence-structure family. Curr Opin Struct Biol 1996; 6: 395-401. (Pubitemid 26197441)
9. Saurin AJ, Borden KL, Boddy M, & Freemont PS. Does this have a familiar RING? Trends Biochem Sci 1996; 21: 208-214
10. Fang S, Lorick KL, Jensen JP, Weissman AM. RING finger ubiquitin protein ligases: implications for tumorigenesis, metastasis and for molecular targets in cancer. Semin Cancer Biol 2003; 13: 5-14. (Pubitemid 36269176)
11. Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 2005; 6: 9-20. (Pubitemid 40064895)
12. Hatakeyama S, Yada M, Matsumoto M, Ishida N, Nakayama KI. U box proteins as a new family of ubiquitin-protein ligases. J Biol Chem 2001; 276: 33111-33120 (Pubitemid 37384765)
13. Coscoy L, Ganem D. PHD domains and E3 ubiquitin ligases: Viruses make the connection. Trends Cell Biol 2003; 13: 7-12. (Pubitemid 35453890)
14. Aravind L, Koonin EV. The U box is a modified RING finger - a common domain in ubiquitination. Curr Biol 2000; 10: 132-134 (Pubitemid 30146770)
15. Brzovic PS, Rajagopal P, Hoyt DW, King MC, Klevit RE. Structure of a BRCA1-BARD1 heterodimeric RING-RING complex. Nat Struct Biol 2001; 10: 833-837 (Pubitemid 32923599)
16. Zheng N, Wang P, Jeffrey PD, Pavletich NP, Structure of a c-Cbl-UbcH7 complex: RING domain function in ubiquitin-protein ligases. Cell 2000; 102: 533-539
17. 4 Motiff an Alpha Herpes Virus Protein Family. J Mol Biol 1993; 234: 1038-1047
18. Barlow PN, Luisi B, Milner A, Elliott M, Everett R. Structure of the C3HC4 domain by 1H-nuclear magnetic resonance spectroscopy. A new structural class of zinc-finger. J Mol Biol 1994; 237: 201-211 (Pubitemid 2050630)
19. Gervais V, Busso D, Wasielewski E, Poterszman A, Egly JM, Thierry JC, et al. Solution structure of the N-terminal domain of the human TFIIH MAT1 subunit: new insights into the RING finger family. J Biol Chem2001; 276: 7457-7464
20. Buchwald G, van der Stoop P, Weichenrieder O, Perrakis A, van Lohuizen M, Sixma TK. Structure and E3-ligase activity of the Ring-Ring complex of polycomb proteins Bmi1 and Ring1b. EMBO J 2006; 25: 2465-2474 (Pubitemid 44012229)
21. Katoh S, Hong C, Tsunoda Y, Murata K, Takai R, Minami E, et al. High precision NMR structure and function of the RING-H2 finger domain of EL5, a rice protein whose expression is increased upon exposure to pathogen-derived oligosaccharides. J Biol Chem 2003; 278: 15341-15348 (Pubitemid 36799873)
22. Mercier P, Lewis MJ, Hau DD, Saltibus LF, Xiao W, Spyracopoulos L. Structure, interactions, and dynamics of the RING domain from human TRAF6. Protein Sci 2007; 4: 602-614 (Pubitemid 46506989)
23. Kandias NG, Chasapis CT, Episkopou V, Bentrop D, Spyroulias GA. High yield expression and NMR characterization of Arkadia E3 ubiquitin ligase RING-H2 finger domain. Biochem Biophys Res Commun 2009; 378: 498-502.
24. Kostic M, Matt T, Martinez-Yamout MA, Dyson HJ, Wright PE. Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53. J Mol Biol 2006; 363: 433-450 (Pubitemid 44436256)
25. Frya DC, Donald Emersona DS, Palmeb S, Vua BT, Liua CM, Podlaski F. NMR structure of a complex between MDM2 and a small molecule Inhibitor. Journal of Biomolecular NMR 2004; 30: 163-173 (Pubitemid 39549733)
26. Dominguez C, Bonvin AM, Winkler GS, van Schaik FM, Timmers HT, Boelens R. Structural model of the UbcH5B/CNOT4 complex revealed by combining NMR, mutagenesis, and docking approaches. Structure 2004; 12: 633-644 (Pubitemid 38447166)
27. Hanzawa H, de Ruwe MJ, Albert TK, van Der Vliet PC, Timmers HT, Boelens R. The structure of the C4C4 ring finger of human NOT4 reveals features distinct from those of C3HC4 RING fingers. J Biol Chem 2001; 276: 10185-10190
28. Ardley HC, Tan NGS, Rose SA, Markham AF, Robinson PA. Features of the Parkin/Ariadne-like ubiquitin ligase, HHARI, which regulate its interaction with the ubiquitin-conjugating enzyme, UbcH7. J Biol Chem 2001; 276: 19640-19647 (Pubitemid 37411305)
29. Huang A, de Jong RN, Wienk H, Winkler GS, Timmers HT and Boelens R. E2-c-Cbl recognition is necessary but not sufficient for ubiquitination activity. J Mol Biol 2009; 385: 507-519
30. Silver DE, Sponopulou E, Mulligan RC, Baltimore D. Dispensable sequence motifs in the RAG-1 and RAG-2 genes for plasmid V(D)J recombination. Proc Natl Acad Sci 1993; 90: 6100-6104 (Pubitemid 23191462)
31. Knipscheer P, Sixma TK. Protein-protein interactions regulate Ubl conjugation. Curr Opin Struct Biol 2007; 17: 665-673 (Pubitemid 350180407)
32. Bellon SF, Rodgers KK, Schatz DG, Coleman JE, Steitz TA. Crystal structure of the RAG1 dimerization domain reveals multiple zinc-binding motifs including a novel zinc binuclear cluster. Nat Struct Biol 1997; 4: 586-591 (Pubitemid 27282155)
33. Buchwald G, van der Stoop P, Weichenrieder O, Perrakis A, van Lohuizen M, Sixma TK. Structure and E3-ligase activity of the Ring-Ring complex of polycomb proteins Bmi1 and Ring1b. EMBO J 2006; 25: 2465-2474 (Pubitemid 44012229)
34. Li Z, Cao R, Wang M, Myers MP, Zhang Y, Xu RM. Structure of a Bmi-1-Ring1B polycomb group ubiquitin ligase complex. J Biol Chem 2006; 281: 20643-20649 (Pubitemid 44065835)
35. Zhang M, Windheim M, Roe SM, Peggie M, Cohen P, Prodromou C, Pearl LH. Chaperoned ubiquitylation - crystal structures of the CHIP U box E3 ubiquitin ligase and a CHIPUbc13- Uev1a complex. Mol Cell 2005; 20: 525-538 (Pubitemid 41668638)
36. Brzovic PS, Keeffe JR, Nishikawa H, Miyamoto K, Fox D 3rd, Fukuda M, et al. Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex. Proc Natl Acad Sci USA 2003; 100: 5646-5651 (Pubitemid 36576862)
37. Pichler A, Knipscheer P, Saitoh H, Sixma TK, Melchior F. The RanBP2 SUMO E3 ligase is neither HECT- nor RING-type. Nat Struct Mol Biol 2004; 11: 984-991 (Pubitemid 39315303)
38. Hao B, Oehlmann S, Sowa ME, Harper JW, Pavletich NP. Structure of a Fbw7-Skp1-cyclin E complex: multisitephosphorylated substrate recognition by SCF ubiquitin ligases. Mol Cell 2007; 26: 131-143 (Pubitemid 46550934)
39. Linke K, Mace PD, Smith CA, Vaux DL, Silke J, Day CL. Structure of the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their ubiquitylation in trans. Cell Death Differ 2008; 15: 841-848
40. Deshaies RJ. SCF and cullin/RING H2-based ubiquitin ligases. Annu Rev Cell Dev Biol 1999; 15: 435-467
41. Seol JH, Feldman RM, Zachariae W, Shevchenko A, Correll CC, Lyapina JS, et al. Cdc53/cullin and the essential Hrt1 RING-H2 subunit of SCF define a ubiquitin ligase module that activates the E2 enzyme Cdc34. Genes Dev 1999; 13: 1614-1626 (Pubitemid 29297928)
42. Ohta T, Michel JJ, Schottelius AJ, Xiong Y. ROC1, a homolog of APC11, represents a family of cullin partners with an associated ubiquitin ligase activity. Mol Cell 1999; 3: 535-541 (Pubitemid 29292611)
43. Pintard V, Willems A, Peter M. Cullin-based ubiquitin ligases: Cul3-BTB complexes join the family. EMBO J 2004; 23: 1681-1687 (Pubitemid 38649631)
44. Zheng N, Schulman BA, Song L, Miller JJ, Jeffrey PD, Wang P, et al. Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. Nature 2002; 416: 703-709 (Pubitemid 34429140)
45. Mizushima T, Yoshida Y, Kumanomidou T, Hasegawa Y, Suzuki A, Yamane T. Structural basis for the selection of glycosylated substrates by SCF (Fbs1) ubiquitin ligase. Proc Natl Acad Sci USA 2007; 104: 5777-5781 (Pubitemid 47175610)
46. Hao B, Oehlmann S, Sowa ME, Harper JW, Pavletich NP. Structure of a Fbw7-Skp1-cyclin E complex: multisitephosphorylated substrate recognition by SCF ubiquitin ligases. Mol Cell 2007; 26: 131-143 (Pubitemid 46550934)
47. Özkan E, Yu H, Deisenhofer J. Mechanistic insight into the allosteric activation of a ubiquitin-conjugating enzyme by RING-type ubiquitin ligases. Proc Natl Acad Sci USA 102 2005; 52: 18890-18895 (Pubitemid 43049537)
48. Liu Z, Haas AL, Diaz LA, Conrad CA, Giudice GJ. Characterization of a novel keratinocyte ubiquitin carrier protein. J Biol Chem 1996; 271: 2817-2822 (Pubitemid 26047902)
49. VanDemark AP, Hofmann RM, Tsui C, Pickartb CM, Wolberger C. Molecular insights into poly-ubiquitin chain assembly: crystal structure of the Mms2/Ubc13 heterodimer. Cell 2001; 105: 711-720 (Pubitemid 32635101)
50. Moraes TF, Edwards RA, McKenna S, Pastushok L, Xiao W, Glover JN, et al. Crystal structure of the human ubiquitin conjugating enzyme complex, hMms2-hUbc13. Nat Struct Biol 2001; 8: 669-673 (Pubitemid 32757924)
51. McKenna S, Moraes T, Pastushok L, Ptak C, Xiao W, Spyracopoulos L, et al. An NMR-based model of the ubiquitin-bound human ubiquitin conjugation complex Mms2-Ubc13. The structural basis for lysine 63 chain catalysis. J Biol Chem 2003; 278: 13151-13158 (Pubitemid 36800083)
52. Lakshmanan M, Bughani U, Duraisamy S, Diwan M, Dastidar S, Ray A. Molecular targeting of E3 ligases - a therapeutic approach for cancer. Expert Opin Ther Targets 2008; 7: 855-870 (Pubitemid 352003325)
53. Pray TR, Parlati F, Huang J, Wong BR, Payan DG, Bennett MK, et al. Cell cycle regulatory E3 ubiquitin ligases as anticancer targets. Drug Resist Updat 2002; 6: 249-258 (Pubitemid 36132806)
54. Yi Sun. Targeting E3 ubiquitin ligases for cancer therapy. Cancer Biol Ther 2003; 2: 623-629
55. Cahilly-Snyder L, Yang-Feng T, Francke U, George DL. Molecular analysis and chromosomal mapping of amplified genes isolated from a transformed mouse 3T3 cell line. Somat Cell Mol Genet 1987; 13: 235-244
56. Freedman DA, Wu L, Levine AJ. Functions of the MDM2 oncoprotein. Cell Mol Life Sci 1999; 55: 96-107.
57. Zhang, Wang H. MDM2 oncogene as a novel target for human cancer therapy. Curr Pharm Des 2000; 6: 393-416.
58. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res 1998; 26: 3453-3459
59. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54: 4855-4878 (Pubitemid 24289415)
60. Giaccia AJ, Kastan MB. The complexity of p53 modulation: Emerging patterns from divergent signals. Genes Dev 1998; 12: 2973-2983
61. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-310
62. Wu X, Bayle JH, Olson D, Levine AJ, The p53-mdm-2 autoregulatory feedback loop. Genes Dev 1993; 7: 1126-1132
63. Fang S, Jensen JP, Ludwig RL, Vousden KH, Weissman AM. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 2000; 275: 8945-8951 (Pubitemid 30180252)
64. Honda R, Yasuda H. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 2000; 19: 1473-1476 (Pubitemid 30171179)
65. Yang Y, Ludwig RL, Jensen JP, Pierre SA, Medaglia MV, Davydov IV, et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 2005; 7: 547-559 (Pubitemid 40799248)
66. Klein C, Vassilev LT. Targeting the p53-MDM2 interaction to treat cancer. Br J Cancer 2004; 91: 1415-1419 (Pubitemid 39486340)
67. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 2006; 103: 1888-1893 (Pubitemid 43228788)
68. Grasberger BL, Lu T, Schubert C, Parks DJ, Carver TE, Koblish HK, et al. Discovery and cocrystal structure of benzodiazepine-dione HDM2 antagonists that activate p53 in cells. J Med Chem 2005; 48: 909-912 (Pubitemid 40270436)
69. Koblish HK, Zhao S, Franks CF, Donatelli RR, Tominovich RM, LaFrance LV, et al. Benzodiazepinedione inhibitors of the Hdm2: p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol Cancer Ther 2006; 5: 160-169
70. Leonard K, Marugan JJ, Raboisson P, Calvo R, Gushue JM, Koblish HK, et al. Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity. Bioorg Med Chem Lett 2006; 16: 3463-3468 (Pubitemid 44226372)
71. Parks DJ, LaFrance LV, Calvo RR, Milkiewicz KL, Marugán JJ, Raboisson P, et al. Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2, 5-dione antagonists of the HDM2-p53 proteinprotein interaction through structure-based drug design. Bioorg Med Chem Lett 2006; 16: 3310-3314 (Pubitemid 44304453)
72. Ding K, Lu Y, Nikolovska-Coleska Z, Qiu S, Ding Y, Gao W, et al. Structure-based design of potent non-peptide MDM2 inhibitors. J Am Chem Soc 2005; 127: 10130-10131 (Pubitemid 41045454)
73. Ding K, Lu Y, Nikolovska-Coleska Z, Wang G, Qiu S, Shangary S, et al. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J Med Chem 2006; 49: 3432-3435 (Pubitemid 43902447)
74. Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004; 10: 1321-1328 (Pubitemid 40022713)
75. Karolinska Institute: WO2004035580 (2004).
76. Guédat P, Colland F. Patented small molecule inhibitors in the ubiquitin proteasome system, BMC Biochemistry 2007; 8: 14. (Pubitemid 351813994)
77. Astra Zeneca: . WO0015657 (2000).
78. Hoffmann-la Roche: WO2004080460 (2004).
79. Janssen: WO2006032631 (2006).
80. Rigel: WO2004043955 (2004).
81. Deng L, Wang C, Spencer E, Yang L, Braun A, You J, et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell 2000; 103: 351-361
82. Chen ZJ. Ubiquitin signalling in the NF-kappaB pathway. Nat Cell Biol 2005; 7: 758-765
83. Rigel: WO2006002284 (2006)
84. Scully R, Livingston DM. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 2000; 408: 429-432
85. Wu LC, Wang ZW, Tsan JT, Spillman MA, Phung A, Xu XL, et al. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat Genet 1996; 14: 430-440
86. Brzovic PS, Keeffe JR, Nishikawa H, Miyamoto K, Fox D 3rd, Fukuda M, et al. Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex. Proc Natl Acad Sci USA 2003; 100: 5646-5651 (Pubitemid 36576862)
87. Xia Y, Pao GM, Chen HW, Verma IM, Hunter T. Enhancement of BRCA1 E3 ubiquitin ligase activity through direct interaction with the BARD1 protein. J Biol Chem 2003; 278: 5255-5263 (Pubitemid 36801039)
88. Brzovic PS, Meza JE, King MC, Klevit RE. BRCA1 RING domain cancer-predisposing mutations. Structural consequences and effects on protein-protein interactions. J Biol Chem 2001; 276: 41399-41406 (Pubitemid 37373302)
89. Hashizume R, Fukuda M, Maeda I, Nishikawa H, Oyake D, Yabuki Y, et al. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. J Biol Chem 2001; 276: 14537-14540 (Pubitemid 37373320)
90. Ruffner H, Joazeiro CA, Hemmati D, Hunter T, Verma IM. Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Natl Acad Sci USA 2001; 98: 5134-5139 (Pubitemid 32397095)
91. Holt JT, Thompson ME, Szabo C, Robinson-Benion C, Arteaga CL, King MC, et al. Growth retardation and tumour inhibition by BRCA1. Nat Genet 1996; 12: 298-302. (Pubitemid 26080089)
92. Tait DL, Obermiller PS, Holt JT. Preclinical studies of a new generation retroviral vector for ovarian cancer BRCA1 gene therapy. Gynecol Oncol 2000; 79: 471-476
93. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005; 434: 913-917 (Pubitemid 40559005)
94. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434: 917-921 (Pubitemid 40559006)
95. Boulton S, Kyle S, Durkacz BW. Interactive effects of inhibitors of poly (ADP-ribose) polymerase and DNA-dependent protein kinase on cellular responses to DNA damage. Carcinogenesis 1999; 20: 199-203. (Pubitemid 29057550)
96. Hartwell LH, Szankasi P, Roberts CJ, Murray AW, Friend SH. Integrating genetic approaches into the discovery of anticancer drugs. Science 1997; 278: 1064-1068 (Pubitemid 27517876)
97. Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer 2005; 5: 689-698
98. Gagne JP, Hendzel MJ, Droit A, Poirier GG. The expanding role of poly (ADP-ribose) metabolism: current challenges and new perspectives. Curr Opin Cell Biol 2006; 18: 145-151 (Pubitemid 43375881)
99. Ame JC, Spenlehauer C, de Murcia G. The PARP superfamily. Bioessays 2004; 26: 882-893
100. Otto H, Reche PA, Bazan F, Dittmar K, Haag F, Koch-Nolte F. In silico characterization of the family of PARP-like poly (ADPribosyl) transferases (pARTs). BMC Genomics 2005; 6: 139.
101. Yap TA, Boss DS, Fong PC, Roelvink M, Tutt A, Carmichael J, O'Connor MJ, et al. First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers. J Clin Oncol 2007; 25: 2007-3529.
102. McCabe N, Lord CJ, Tutt AN, Martin NM, Smith GC, Ashworth A. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency. Cancer Biol Ther 2005; 4: 934-936 (Pubitemid 41598586)
103. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, et al. ABT- 888, an orally active poly (ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007; 13: 2728-2737 (Pubitemid 46795129)
104. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008; 451: 1111-1115 (Pubitemid 351317441)
105. Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Current Opinion in Pharmacology 2008; 8: 363-369
106. Alroy I, Tuvia S, Greener T, Gordon D, Barr HM, Taglicht D. The trans-Golgi network-associated human ubiquitin-protein ligase POSH is essential for HIV type 1 production. Proc Natl Acad Sci USA 2005; 102(5): 1478-1483 (Pubitemid 40209195)
107. Proteologics: WO2005007141 (2005).
108. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med 2000; 342: 1350-1358 (Pubitemid 30408720)
109. Mavrakis KJ, Andrew RL, Lee KL, Petropoulou C, Dixon JE, Navaratnam N, et al. Arkadia enhances Nodal/TGF-b signaling by coupling phospho-Smad2/3 activity and turnover. PLOS Biol 2007; 5: 586-603. (Pubitemid 46422976)
110. Koinuma D, Shinozaki M, Komuro A, Goto K, Saitoh M, Hanyu A, et al. Arkadia amplifies TGF-beta superfamily signalling through degradation of Smad7. EMBO J 2003; 22: 6458-6470 (Pubitemid 38009594)
111. Levy L, Howell M, Das D, Harkin S, Episkopou V, Hill CS. Arkadia activates Smad3/Smad4-dependent transcription by triggering signal-induced SnoN degradation. Mol Cell Biol 2007; 27: 6068-6083 (Pubitemid 47326695)
112. Nagano Y, Mavrakis KJ, Lee KL, Fujii T, Koinuma D, Sase H, et al. Arkadia induces degradation of SnoN and c-Ski to enhance transforming growth factor-beta signaling. J Biol Chem 2007; 282: 20492-20501 (Pubitemid 47100041)
113. Luo K. Ski and SnoN: negative regulators of TGF-beta signaling. Curr Opin Genet Dev 2004; 14: 65-70. (Pubitemid 38167479)
114. Pot I, Bonni S. SnoN in TGF-beta signaling and cancer biology. Curr Mol Med 2008; 8: 319-328 (Pubitemid 351982535)
115. Derynck R, Akhurst RJ, Balmain A. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117-129 (Pubitemid 32952643)
116. Xie W, Mertens JC, Reiss DJ, Rimm DL, Camp RL, Haffty BG, et al. Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res 2002; 62: 497-505. (Pubitemid 34106424)
117. Kalkhoven E, Roelen BA, de Winter JP, Mummery CL, van den Eijndenvan Raaij AJ, van der Saag PT, et al. Resistance to transforming growth factor beta and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth Differ 1995; 6: 1151-1161
118. Kitching R, Gish G, Burger A, Landberg G, Seth A. The RING-H2 protein RNF11 is differentially expressed in breast tumors and interacts with HECT-type E3 ligases. Biochim Biophys Acta 2003; 1639: 104-112 (Pubitemid 38366214)
119. Li H-X, Seth A. An RNF11: Smurf2 complex mediates ubiquitination of the AMSH protein. Oncogene 2004; 23: 1801-1808 (Pubitemid 38445405)
120. Subramaniam V, Lubovitz J, Li H-X, Burger A, Kitching, R, Seth A. The RING-H2 protein RNF11 is overexpressed in breast cancer and is a target of Smurf2 E3 ligase. Br J Cancer 2003; 189: 1538-1544 (Pubitemid 37386612)
121. Hayashi H, Abdollah S, Qiu Y, Cai J, Xu YY, Grinnell BW, et al. The MAD-related protein Smad7 associates with the TGFbeta receptor and functions as an antagonist of TGFbeta signaling. Cell 1997; 89: 1165-1173 (Pubitemid 127678749)
122. Kavsak P, Rasmussen RK, Causing CG, Bonni S, Zhu H, Thomsen GH, et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 2000; 6(6): 1365-1375 (Pubitemid 32045929)
123. Colland F, Jacq X, Trouplin V, Mougin C, Groizeleau C, Hamburger A, et al. Functional proteomics mapping of a human signaling pathway. Genome Res 2004; 14: 1324-1332 (Pubitemid 39029229)
124. Burger A, Li H, Zhang XK, Pienkowska M, Venanzoni M, Vournakis J, et al. Breast cancer genome anatomy: correlation of morphological changes in breast carcinomas with expression of the novel gene product Di12. Oncogene 1998; 16: 327-333 (Pubitemid 28052287)
125. Diamonti AJ, Guy PM, Ivanof C, Wong K, Sweeney C, Carraway KL 3rd. An RBCC protein implicated in maintenance of steady-state neuregulin receptor levels. Proc Natl Acad Sci USA 2002; 99: 2866-2871
126. Qiu XB, Goldberg AL. Nrdp1/FLRF is a ubiquitin ligase promoting ubiquitination and degradation of the epidermal growth factor receptor family member, ErbB3. Proc Natl Acad Sci USA 2002; 99: 14843-14848
127. Sweeney C, Carraway KL 3rd. Negative regulation of ErbB family receptor tyrosine kinases. Br J Cancer 2004; 90: 289-293 (Pubitemid 38250616)
128. Thien CB, Blystad FD, Zhan Y, Lew AM, Voigt V, Andoniou CE, et al. Loss of c-Cbl RING finger function results in high-intensity TCR signaling and thymic deletion. EMBO J 2005; 24: 3807-3819 (Pubitemid 41581696)
129. Levkowitz G, Waterman H, Ettenberg SA, Katz M, Tsygankov AY, Alroy I, et al. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol Cell 1999; 4: 1029-1040 (Pubitemid 30054908)
130. Mosesson Y, Shtiegman K, Katz M, Zwang Y, Vereb G, Szollosi J, et al. Endocytosis of receptor tyrosine kinases is driven by monoubiquitylation, not polyubiquitylation. J Biol Chem 2003; 278: 21323-21326 (Pubitemid 36792525)
131. Mocchegiani E, Malavolta M, Muti E, Costarelli L, Cipriano C, Piacenza F, et al. Zinc, metallothioneins and longevity: interrelationships with niacin and selenium. Curr Pharm Des 2008; 14(26): 2719-2732
132. Supuran CT. Carbonic anhydrases - an overview. Curr Pharm Des 2008; 14(7): 603-614
133. Winum JY, Scozzafava A, Montero JL, Supuran CT. Design of zinc binding functions for carbonic anhydrase inhibitors. Curr Pharm Des 2008; 14(7): 615-621 (Pubitemid 351736440)